Director of Infection Prevention and Control Annual Report
Meeting: |
Trust Public Board |
Date: |
08.11.2023 |
|
Report Title: |
Director of Infection Prevention and Control annual report |
|||
Agenda Item: |
4.4 |
SR1a: If we do not ensure our people are safe and their wellbeing prioritised, there is a risk that we will be unable to attract, retain and keep all our people safe and well |
X |
|||||||||||
SR1b: If we do not ensure our leaders are developed and equipped, there is a risk that we will not be able to change our culture, and value, support, develop and grow our people |
|
|||||||||||
SR2: If we do not deliver operational and clinical standards then there is a risk of poor patient outcomes and experience |
X |
|||||||||||
SR3: If we do not ensure we have the ability to plan, influence and deliver across our systems to secure change, we will not be able to meet the needs of our public and communities |
X |
|||||||||||
SR4: If we do not resolve long standing organisational inefficiencies we will be unable to deliver an effective, sustainable, value for money service to our public |
X |
|||||||||||
SR5: If we do not clearly define our strategic plans we will not have the agility to deliver the suite of improvements needed |
X |
|||||||||||
Equality Impact Assessment |
||||||||||||
No negative impact identified |
X |
|
||||||||||
Recommendation: |
||||||||||||
The Board is asked to acknowledge and note the DIPC annual report for information. |
||||||||||||
Previously considered by: |
||||||||||||
QGC, IP&C Group, Compliance and Risk Group |
||||||||||||
Purpose |
||||||||||||
The purpose of this paper is to request for review and agreement/feedback in relation to the annual Director of IPC report. |
||||||||||||
Executive Summary |
||||||||||||
The DIPC annual report is an accurate account of the Trust’s Infection, Prevention and Control activities. In developing this annual report, we have set out a summary of achievements for 2022/23, and goals for 2023/24. |
||||||||||||
Introduction/ Background | ||||||||||||
The report has been shared with and approved by the Infection, Prevention and Control Group. The report has also been approved at Compliance and Risk Group. |
||||||||||||
Key Issues/ Risks | ||||||||||||
|
||||||||||||
Options | ||||||||||||
Not applicable. | ||||||||||||
Summary | ||||||||||||
As per Executive Summary. |
Next Section: Performance and Finance Committee Assurance Report